Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. - Wikidata - wikimedia - TriplyDB

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.

http://www.wikidata.org/entity/Q37711782

about

Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes.

P2860

Q47614980-6A9E4133-AD9A-4714-83BE-0D38C0E695FA Q55018505-82340C85-50ED-4DB5-9B62-A99967541CFC

P2860

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations.

http://www.wikidata.org/entity/Q37711782

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@en

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@nl

type

label

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@en

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@nl

prefLabel

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@en

Panobinostat acts synergistica ...... lls with MyD88 L265 mutations.

@nl

P1433

Q37711782-A143273B-250D-4F28-BC94-933626C9907B

P1476

Q37711782-2C658D67-E1E4-4517-9A77-9B89A06FB628

P2093

Q37711782-185B6591-0193-4813-8123-CF9D31628EDE

Q37711782-1B434888-F71E-47B6-883D-E41AE4548A42

Q37711782-3394B10D-E8EB-4087-A6DF-D6781A419DF1

Q37711782-4FC3F3CA-0B55-42EF-9545-3138E430D89E

Q37711782-829718EA-37EC-4CD4-90C8-B1611ACF0780

Q37711782-883B1E7F-6F52-4084-9E46-995CB648ED37

Q37711782-9720BDEA-08B3-4A9C-B197-7E222B9880B0

Q37711782-AAA03FFE-2600-4346-942B-727A54A33129

Q37711782-AD518BD2-5417-43A1-B86C-3AEF2270F0F9

Q37711782-B30EDDEB-C3A5-49C1-A606-E6C55F8F335E

P2860

Q37711782-0812287C-ACE4-4492-ADC2-9E60E0C8AFDB

Q37711782-1D613A7B-C1F7-4356-BDD7-C75FDCD41DCE

Q37711782-271A2D4C-8564-48DC-ACCF-492BAA8D392F

Q37711782-3DFA35E6-A962-4D6E-B691-B60A4EF99334

Q37711782-40AB02D8-615D-433C-BBF3-A987DECD1447

Q37711782-43785D89-B676-4302-9933-4FA5760EF07B

Q37711782-479FAB76-F3B0-4B28-A22D-4A2A39367376

Q37711782-54C64E47-7A85-4A30-9849-01D7889E673E

Q37711782-7D050B98-DD1B-49A5-8B03-8263EC8769ED

Q37711782-807390BB-5E70-4D8B-8212-32CCFA622743

P304

Q37711782-369D29C1-E9FC-4C94-BA88-51BC843CAA4A

P31

Q37711782-200406F6-89A7-47A3-B59C-B2BE1BABF862

P356

Q37711782-E03AD941-E0D2-467A-A0C2-533F20B464BD

P433

Q37711782-1F9A1578-1BA8-439D-848F-7CA4CFB6DFE4

P478

Q37711782-7519C1B6-8A46-41F0-95D7-89ADA111E4CC

P50

Q37711782-2A882297-3754-4FF6-A584-6E48396C8DA3

P577

Q37711782-EC02BE60-A103-4D74-8078-71CB7970E05D

P698

Q37711782-2046B32B-93E6-481D-97C5-BA93C5676175

P932

Q37711782-10175C7A-97EC-4E84-852B-570663C59099

P356

JCI.INSIGHT.90196

P1433

P1476

Panobinostat acts synergistica ...... lls with MyD88 L265P mutations

@en

P2093

Aaron Y Chang

http://www.w3.org/2001/XMLSchema#string

Anas Younes

http://www.w3.org/2001/XMLSchema#string

David A Scheinberg

http://www.w3.org/2001/XMLSchema#string

Elisa De Stanchina

http://www.w3.org/2001/XMLSchema#string

Eneda Toska

http://www.w3.org/2001/XMLSchema#string

Hans-Guido Wendel

http://www.w3.org/2001/XMLSchema#string

José Baselga

http://www.w3.org/2001/XMLSchema#string

Myles Fennell

http://www.w3.org/2001/XMLSchema#string

Patrizia Mondello

http://www.w3.org/2001/XMLSchema#string

Ralph Garippa

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Ibrutinib in previously treated Waldenström's macroglobulinemia.

Oncogenically active MYD88 mutations in human lymphoma

The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

P304

e90196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI.INSIGHT.90196

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28352655

http://www.w3.org/2001/XMLSchema#string

P932

5358483

http://www.w3.org/2001/XMLSchema#string